Public consultation on applications to be considered by the MSAC PASC (April 2023)

Overview

Consultation is now open for applications that are anticipated to be considered by the PICO Advisory Sub-Committee (PASC) of the Medical Services Advisory Committee (MSAC) on 13-14 April 2023.

PASC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.   

It is anticipated that the below-mentioned applications will proceed to PASC in April 2023. Consultation input must be received by no later than Friday, 10 March 2023 for it to be considered by PASC. A consultation survey form is available on the relevant application webpage.

Further information on MSAC’s consultation process is also available on the MSAC website.

Applications scheduled to be considered:

1728 – Etranacogene dezaparvovec for the treatment of Haemophilia B

1734 – Intravascular lithotripsy for the treatment of moderately or severely calcified peripheral artery disease

1739 – Percutaneous electrical nerve stimulation therapy for chronic neuropathic pain

1740 – N-Terminal-pro Brain Natriuretic Peptidete (NT-proBNP) to aid in the diagnosis of patients with suspected heart failure in a non-hospital setting

1741 – Continuous nerve blockade using a catheter technique

1744 – 177Lutetium (nca) Octreotate treatment for advanced neuroendocrine and other high somatostatin receptor expressing tumours

What happens next

Once the consultation closes, all submissions received will be compiled and summarised in the draft PICO Confirmation that sets out the proposed parameters upon which the assessment is based.

The PASC meets to discuss the draft PICO Confirmation and the consultation comments that have been received.

Once the PICO Confirmation is ratified by the PASC, the PICO Confirmation is published on the relevant application webpage on the MSAC website.